Program
oleclumab
Also written as “Oleclumab”, “Durvalumab + Oleclumab” and “E2 - mFOLFOX6, durvalumab and oleclumab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma · Colonic Neoplasms, led by AstraZeneca.
Furthest: phase 3, since Jan 14, 20228 company-led studies, 4 open or runningNext primary completion: Jan 8, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 84 open or running | phase 3since Jan 14, 2022 | Sep 22, 2017 | Jan 8, 2027phase 3 · NCT05221840 |
- Named in AstraZeneca’s own pipeline as
oleclumab
, phase 3, as of Oct 30, 2026 (source).
Also a collaborator on its studies: parexel.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 22, 2017First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03334617 · 528 enrolled · United States, Austria, Canada and more
- May 18, 2018Phase 2 study in CarcinomaNCT03611556 · 213 enrolled · United States, Australia, Norway and more
- Nov 7, 2018Phase 1 study in Advanced Solid MalignanciesNCT03736473 · 6 enrolled · Japan
- Dec 10, 2018Phase 2 study in Carcinoma, Non-Small-Cell LungNCT03822351 · 189 enrolled · United States, Canada, France and more
- Oct 16, 2019Phase 2 study in Colonic NeoplasmsNCT04145193
- Sep 20, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05061550 · 630 planned · United States, Belgium, Canada and more
- Jan 14, 2022Phase 3 study in Carcinoma, Non-Small-Cell LungNCT05221840 · 1,051 enrolled · United States, Australia, Brazil and more
- Sep 18, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06606847 · 30 enrolled · Russia
- Nov 4, 2026Primary completion moved from 2026-09-30 to 2027-01-08Date moved laterphase 3 · +3 months · NCT05221840
Ahead
- Jan 8, 2027Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT05221840
- May 28, 2030Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05061550
TargetBeta
“A monoclonal antibody against the ectoenzyme CD73 (cluster of differentiation 73), also known as 5'-nucleotidase (5'-NT; ecto-5'-nucleotidase) with potential antineoplastic activity. Upon administration, oleclumab targets and binds to CD73, leading to clustering of and internalization of CD73. Th…”NCIt, read by Claude
Other programs on NT5E
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| quemliclustatrule | Arcus Biosciences | phase 3 | 7 |
| uliledlimabrule | tj-biopharma-co-ltd | phase 3 | 4 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06606847Carcinoma, Non-Small-Cell Lung · Russia | 2 | Active, not recruiting | May 4, 2026 | 30 |
| NCT05221840Carcinoma, Non-Small-Cell Lung · United States, Australia, Brazil and more | 3 | Active, not recruiting | Jan 8, 2027 | 1,051 |
| NCT05061550Carcinoma, Non-Small-Cell Lung · United States, Belgium, Canada and more | 2 | Recruiting | May 28, 2030 | 630 |
| NCT04145193Colonic Neoplasms | 2 | Withdrawn | Mar 19, 2024 | 0 |
| NCT03822351Carcinoma, Non-Small-Cell Lung · United States, Canada, France and more | 2 | Completed | Jul 18, 2023 | 189 |
| NCT03736473Advanced Solid Malignancies · Japan | 1 | Completed | Jun 19, 2019 | 6 |
| NCT03611556Carcinoma · United States, Australia, Norway and more | 2 | Completed | Jul 22, 2022 | 213 |
| NCT03334617Carcinoma, Non-Small-Cell Lung · United States, Austria, Canada and more | 2 | Active, not recruiting | Sep 13, 2024 | 528 |
How it is read
Names in the registry
- “Oleclumab”, 5 entries
- “Durvalumab + Oleclumab”, 1 entry
- “E2 - mFOLFOX6, durvalumab and oleclumab”, 1 entry
- “MEDI9447 (oleclumab)”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 5 studies
- Carcinoma, 1 study
- Colonic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.